Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT04770532
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Ternopil, Ukraine
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1085
- Registration Number
- NCT04760626
- Locations
- 🇺🇸
Cedar-Crosse Research Center, Chicago, Illinois, United States
🇬🇷Iatriko Psychicou Private Clinic, Athens, Greece
🇬🇷Korgiallenio - Benakio Hospital (Red Cross Hosp.), Athens, Greece
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT04722653
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1606
- Registration Number
- NCT04707469
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇨🇦LMC ClinRsrh Inc.Brampton, Brampton, Ontario, Canada
🇮🇳Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT04698018
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇭🇰Phase 1 Clinical Trial Centre, Shatin, New Territories, Hong Kong
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT04682145
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04676906
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 359
- Registration Number
- NCT04666987
- Locations
- 🇮🇹
A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ospedale Camberlingo, Francavilla Fontana, Italy
🇮🇹Ospedale Santa Maria Goretti - UOD Diabetologia, Latina, LT, Italy
A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT04655690
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT04656106
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of